NCT05528796
Uncovering the Etiologies of Non-immune Hydrops Fetalis
Enrolling by Invitation
NAAges 18–60InterventionalDiagnosticUniversity of California, San FranciscoInvestigator-initiated
~500 participants
Updated 2026-04-17 on ClinicalTrials.gov
What's tested:Whole genome sequencing
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of cases for whom a genetic disease or novel variants were identified for underlying NIHF
Measured over 1-3 months
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Teresa Sparks, MD · PRINCIPAL_INVESTIGATOR · UCSF Department of Obstetrics, Gynecology and Reproductive Sciences
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Pregnant individuals whose fetus has been diagnosed with NIHF and standard prenatal testing with karyotype and/or microarray is non-diagnostic
Neonates who received a prenatal diagnosis of NIHF, but genetic testing was unable to be completed or was deferred until after delivery
Exclusion
hydrops secondary to twin-twin transfusion syndrome,
a clear viral etiology, or
alloimmunization.
What this trial measures
- Number of cases for whom a genetic disease or novel variants were identified for underlying NIHF1-3 months
Cases with NIHF for whom pathogenic or likely pathogenic variants were identified implicating genetic disease